Figure 1.
Flow Diagram of Meta-Analysis.
Figure 2.
RRs and 95% CIs of TLR (A) and TVR (B) associated with SES versus PES.
Short-term (≤1 year), long-term (>1 year), and overall-term TLR and TVR in patients treated with SES versus PES were evaluated. Adj-OS = adjusted observational study; CI = confidence interval; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent; TLR = target lesion revascularization; TVR = target vessel revascularization.
Figure 3.
RRs and 95% CIs of other clinical endpoints associated with SES versus PES.
MACE (A), MI (B), all-cause death (C), cardiac death (D), death/MI (E) were evaluated in Short-term (≤1 year), long-term (>1 year), and overall-term follow-up. Adj-OS = adjusted observational study; CD = cardiac death; CI = confidence interval; Death + MI = the composite of death and myocardial infarction; MACE = major adverse cardiac event; MI = myocardial infarction; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent.
Figure 4.
RRs and 95% CIs of stent thrombosis associated with SES versus PES.
Short-term (≤1 year), long-term (>1 year), and overall-term stent thrombosis in patients treated with SES versus PES were evaluated. Short-term stent thrombosis was divided into early (≤30 days) and late (30 days-1 year) stages. Adj-OS = adjusted observational study; CI = confidence interval; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent; ST = stent thrombosis.
Figure 5.
RRs/WMDs and 95% CIs of angiographic endpoints associated with SES versus PES.
Angiographic outcomes were in-segment restenosis (A), in-stent restenosis (A), and in-segment late lumen loss (B), in-stent late lumen loss (B). Short-term (≤1 year), long-term (>1 year), and overall-term angiographic endpoints in patients treated with SES versus PES were evaluated. The overall population and subgroups of diabetes mellitus, acute myocardial infarction, and long lesion were included. Adj-OS = adjusted observational study; CI = confidence interval; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent; WMD = weighted mean difference.
Figure 6.
RRs and 95% CIs of clinical endpoints associated with SES versus PES in diabetes population.
Adj-OS = adjusted observational study; CD = cardiac death; CI = confidence interval; Death + MI = the composite of death and myocardial infarction; DM = diabetes mellitus; MACE = major adverse cardiac event; MI = myocardial infarction; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent; ST = stent thrombosis; TLR = target lesion revascularization; TVR = target vessel revascularization.
Figure 7.
RRs and 95% CIs of clinical endpoints associated with SES versus PES in patient with AMI and long-lesions.
Adj-OS = adjusted observational study; AMI = acute myocardial infarction; CD = cardiac death; CI = confidence interval; MACE = major adverse cardiac event; MI = myocardial infarction; No. = number of the studies; Non-adj OS = non-adjusted observational study; PES = paclitaxel-eluting stents; RCT = randomized controlled trial; RR = relative risk; SES = sirolimus-eluting stent; ST = stent thrombosis; TLR = target lesion revascularization; TVR = target vessel revascularization.